Skip to content

David R Schreier

3 papers in the library · 13 citations · publishing 2025-2026

Papers

Sort Most recent Most cited

Covert brain complexity in the intensive care unit.

Cortex; a journal devoted to the study of the nervous system and behavior August 1, 2026 Matteo Fecchio, David R Schreier, Morgan K Cambareri et al.

Early detection of consciousness in critically ill patients with severe brain injuries can profoundly impact prognostication and clinical care decisions. Advanced multimodal protocols to detect signs of consciousness include standardized behavioral assessments, task-based functional magnetic resonance imaging (fMRI), and task-based electroencephalography (EEG). However, these approaches have...

Anesthetics as Treatments for Depression: Clinical Insights and Underlying Mechanisms.

Annual Review of Neuroscience February 19, 2025 Macauley Smith Breault, Sirma Orguc, Ohyoon Kwon et al. 13 citations

Major depressive disorder and treatment-resistant depression are significant worldwide health problems that need new therapies. The success of the anesthetic ketamine as an antidepressant is well known. It is less widely known that several other anesthetic agents have also shown antidepressant effects. These include nitrous oxide, propofol, isoflurane, sevoflurane, dexmedetomidine, and xenon....

REcovery from DEXmedetomidine-Induced Unresponsiveness (REDEX): A Study Protocol for a Single Center, Parallel Arm, Non-Randomized, Controlled Pilot Trial in Healthy Volunteers.

Nature and Science of Sleep 2025 David R Schreier, Matteo Fecchio, Christian S Guay et al.

Dexmedetomidine (DEX) is a well-tolerated sedative drug that induces a sleep-like state. DEX sedation offers a model to study transitions between different states of consciousness (indicated by, eg, behavior, the electroencephalogram (EEG), or transcranial magnetic stimulation (TMS) evoked EEG responses). However, the effects of repeated DEX exposure on recovery are poorly understood and will...